ASTELLAS PHARMA UNSP.ADR (YPHA) — Net Asset Quality Index
ASTELLAS PHARMA UNSP.ADR (YPHA) has a Net Asset Quality Index of 45.3% as of March 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €3.34 Trillion minus total liabilities of €1.83 Trillion yields net assets of €1.51 Trillion. A higher index indicates a stronger, lower-leverage balance sheet. Check ASTELLAS PHARMA UNSP.ADR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
ASTELLAS PHARMA UNSP.ADR Net Asset Quality Index Over Time (2022–2025)
This chart shows how ASTELLAS PHARMA UNSP.ADR's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of March 2025, the index stands at 45.3%, representing net assets of €1.51 Trillion against total assets of €3.34 Trillion EUR. See ASTELLAS PHARMA UNSP.ADR (YPHA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for ASTELLAS PHARMA UNSP.ADR (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for ASTELLAS PHARMA UNSP.ADR from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of ASTELLAS PHARMA UNSP.ADR.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 45.3% | €1.51 Trillion | €3.34 Trillion | €1.83 Trillion | ▲ +0.6 pp |
| 2024 | 44.7% | €1.60 Trillion | €3.57 Trillion | €1.97 Trillion | ▼ -16.7 pp |
| 2023 | 61.4% | €1.51 Trillion | €2.46 Trillion | €948.56 Billion | ▼ -1.2 pp |
| 2022 | 62.6% | €1.46 Trillion | €2.33 Trillion | €872.09 Billion | — |